Previously submitted to: Journal of Medical Internet Research (no longer under consideration since Jul 24, 2023)
Date Submitted: Jun 20, 2023
Open Peer Review Period: Jun 20, 2023 - Jul 5, 2023
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Impact of Telehealth for Monitoring Depressive Symptom Trajectories in COVID-19 Patients with Clinically Mild Condition in South Korea: Longitudinal Data Analysis
ABSTRACT
Background:
During the height of the COVID-19 pandemic, the Korean government temporarily allowed full scale telehealth care for safety and usability. However, limited studies have evaluated the impact of telehealth by analyzing the physical and/or mental health data of patients with COVID-19 diagnosis collected through telehealth targeting Korean population.
Objective:
This study aimed to identify subgroups of depressive symptom trajectories in patients with clinically mild COVID-19 using collected longitudinal data from a telehealth-based contactless clinical trial.
Methods:
A total of 199 patients with COVID-19 participated in the study. The data were collected from March 23 to July 20, 2022 through the contactless clinical trial using telehealth. Depressive symptoms were measured using the patient health questionnaire-9 on the start day of quarantine, on the final day of quarantine, and one month after release from quarantine. Additionally, acute COVID-19 symptoms were assessed on every quarantine day. The study used a latent class mixed model to differentiate subgroups of depressive symptom trajectories and a logistic regression model with Firth’s correction to identify associations between acute COVID-19 symptoms and the subgroups.
Results:
Two latent classes were identified: class 1 with declining linearity at a slow rate and class 2 with increasing linearity. Among COVID-19 symptoms, fever, chest pain, and brain fog one month after release from quarantine showed strong associations with class 2 (fever: OR, 19.43, 95% CI, 2.30–165.42; chest pain: OR, 6.55, 95% CI, 1.15–34.61; brain fog: OR, 7.03, 95% CI 2.57–20.95). Sleeping difficulty and gastrointestinal symptoms were also associated with class 2 (gastrointestinal symptoms: OR, 4.76, 95% CI, 1.71–14.21; sleeping difficulty: OR, 3.12, 95% CI, 1.71–14.21).
Conclusions:
These findings emphasize the need for the early detection of depressive symptoms in patients in the acute phase of COVID-19 using telemedicine. Active intervention using digital therapeutics may also be required for patients with aggravated depressive symptoms.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.